retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Retatrutide: A Triple Agonist Shaping

Kuo B, Scimia C, Dukes G et al (2021) Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D2 /D3 receptor antagonist, in patients with gastroparesis

A brief overview of the key findings is provided below

Insulin drug pricing is a major concern in many countries, and Germany is no exception

Aaron Erez explains: "Medication cant outpace an unhealthy lifestyle in the long run

Generalizations such as one patient out of 10 had developed aspiration should not have been assumed as a 10% risk of aspiration for patients on GLP-1 RAs exists due to the sample size, for example

Consequently, observed reductions in cancer incidenceparticularly for colorectal and liver cancers should be interpreted with caution and cannot be assumed to reflect long-term cancer prevention